Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Nature Nanotechnology|October 8, 2009
Diagnosing lung cancer in exhaled breath using gold nanoparticlesGang Peng, Ulrike Tisch, Orna Adams, et al.
Breast Cancer Research and Treatment|December 31, 2010
Classification of breast cancer precursors through exhaled breathGregory Shuster, Zahava Gallimidi, Asnat Heyman Reiss, et al.
Cancer|October 5, 2002
Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000Eliahu Gez, Raphael Rubinov, Diana Gaitini, et al.
The American Journal of the Medical Sciences|December 19, 2008
Small cell (neuroendocrine) carcinoma of the prostate: etiology, diagnosis, prognosis, and therapeutic implications--a retrospective study of 30 patients from the rare cancer networkMoshe E Stein, Zvi Bernstein, Ufuc Abacioglu, et al.
International Journal of Radiation Oncology, Biology, Physics|February 4, 2012
Outcome and prognostic factors in endometrial stromal tumors: a Rare Cancer Network studyUlrike Schick, Yasmin Bolukbasi, Juliette Thariat, et al.
Rare Tumors|July 22, 2016
Outcome and Predictive Factors in Uterine Carcinosarcoma Using Postoperative Radiotherapy: A Rare Cancer Network StudyDaniel R Zwahlen, Ulrike Schick, Yasemin Bolukbasi, et al.
European Journal of Cancer (Oxford, England : 1990)|July 15, 2004
Late toxicity following conventional radiotherapy for prostate cancer: analysis of the EORTC trial 22863Fatma Ataman, Alfredo Zurlo, Xavier Artignan, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 19, 2008
Impact of the boost dose of 10 Gy versus 26 Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trialPhilip M Poortmans, Laurence Collette, Jean-Claude Horiot, et al.
The Israel Medical Association Journal : IMAJ|March 15, 2013
Targeted therapy with low doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastomaMyriam Weyl Ben-Arush, Ayelet Ben Barak, Raquel Bar-Deroma, et al.
Lancet (London, England)|July 20, 2002
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trialMichel Bolla, Laurence Collette, Léo Blank, et al.
Pageof 7